Aintzane
Zabaleta Azpiroz
Investigadora Asociada
Publicaciones (40) Publicaciones de Aintzane Zabaleta Azpiroz
2024
-
A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies
British Journal of Haematology
-
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096
-
Hypocortisolemic ASIA: a vaccine- and chronic infection-induced syndrome behind the origin of long COVID and myalgic encephalomyelitis
Frontiers in Immunology, Vol. 15
-
Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19
Blood Cancer Journal, Vol. 14, Núm. 1
-
Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells
British Journal of Haematology, Vol. 205, Núm. 4, pp. 1346-1355
-
Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia
Blood Advances
2023
-
Epstein–Barr virus-acquired immunodeficiency in myalgic encephalomyelitis—Is it present in long COVID?
Journal of Translational Medicine, Vol. 21, Núm. 1
-
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study
The Lancet Oncology, Vol. 24, Núm. 8, pp. 913-924
-
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
Nature Communications, Vol. 14, Núm. 1
-
Redox-Triggered Nanomedicine via Lymphatic Delivery: Inhibition of Melanoma Growth by Ferroptosis Enhancement and a Pt(IV)-Prodrug Chemoimmunotherapy Approach
Advanced Therapeutics, Vol. 6, Núm. 2
2022
-
FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
Blood Advances, Vol. 6, Núm. 2, pp. 690-703
2021
-
Epstein-Barr Virus and the Origin of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome
Frontiers in Immunology, Vol. 12
-
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies
Blood Cancer Journal, Vol. 11, Núm. 12
-
Immunologic characterization of COVID-19 patients with hematological cancer
Haematologica
-
Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients
Frontiers in Immunology, Vol. 12
2020
-
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Blood, Vol. 136, Núm. 2, pp. 199-209
2019
-
Analysis of monocitary subpopulations in relation to cardiovascular risk factors
Clinica e Investigacion en Arteriosclerosis, Vol. 31, Núm. 4, pp. 152-159
-
Análisis de subpoblaciones monocitarias en relación con los factores de riesgo cardiovascular
Clínica e investigación en arteriosclerosis, Vol. 31, Núm. 4, pp. 152-159
-
Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells
OncoImmunology, Vol. 8, Núm. 7
-
Immunophenotypic Pattern of De Novo Malignancy After Liver Transplantation
Transplantation Proceedings, Vol. 51, Núm. 1, pp. 77-79